Results 121 to 130 of about 5,257 (166)

Tolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18-35 Years: A Pooled Database Analysis. [PDF]

Kidney Med
Chebib FT, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S, Oberdhan D, Fernandes AW.   +7 more
europepmc   +1 more source

Liver safety of tolvaptan in patients with autosomal dominant polycystic kidney disease: interim data from a post-authorization safety study. [PDF]

Clin Kidney J
Jaeger T, Lohrmann E, Ezenekwe A, Enekebe K, Kumar R, Nunna S, Fernandes AW, McCormick L, George V.   +8 more
europepmc   +1 more source

Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan. [PDF]

Kidney Int Rep
Uchiyama K, Kamano D, Nagasaka T, Hama EY, Shirai R, Sumura R, Kusahana E, Yanai A, Nakayama T, Kimura T, Takahashi R, Kasai T, Tajima T, Hosoya K, Azegami T, Yamaguchi S, Yoshino J, Ito J, Hayashi M, Kanda T, Ishibashi Y, Washida N, Itoh H, Hayashi K.   +23 more
europepmc   +1 more source

Trajectory of Urine Parameters by Adding Herbal Kampo Medicine Goreisan to Tolvaptan in Patients with Congestive Heart Failure. [PDF]

J Clin Med
Kakeshita K, Imamura T, Hida Y, Onoda H, Koike T, Kinugawa K.   +5 more
europepmc   +1 more source

Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD. [PDF]

Kidney Int Rep
Geertsema P, Soonawala D, Gansevoort RT, Meijer E.   +3 more
europepmc   +1 more source

Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial. [PDF]

BMJ Open
Bahlmann-Kroll E, Häckl S, Kramer S, Wulfmeyer VC, Glandorf J, Kaufeld J, Koch A, Hartung D, Schmidt BMW, Schmidt-Ott K, Schmitt R.   +10 more
europepmc   +1 more source

Predictors for Tolvaptan Treatment and Future Perspectives

International Heart Journal, 2016
openaire   +4 more sources

Cost-Minimization Analysis of Tolvaptan Treatment for ADPKD in Southern Spain. [PDF]

Kidney Int Rep
Roca Oporto FJ, Espín J, Andrades Gómez C, Montilla Cosano G, Sánchez-Pozo MC, Rocha JL.   +5 more
europepmc   +1 more source

Tolvaptan-related toxicoderma

Nefrología (English Edition)
Alba Rivas Oural, Jose Joaquín Bande Fernández, Luis Fernando Morán Fernández, Sheila Requena López, Blanca Vivanco Allende, Elena Astudillo Cortés   +5 more
openaire   +1 more source